Companies may potentially accelerate the approval of generic drugs by avoiding deficiencies in ANDA submissions.
Rong-Kun Chang
Advertisement
Rong-Kun Chang, PhD, is associate director at Supernus Pharmaceuticals.
Articles by Rong-Kun Chang
Advertisement
Latest Updated Articles
Common Deficiencies in ANDAs for Dermatologic Drug ProductsPublished: September 2nd 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Drug Digest: Strategic Alliances and Technology Integration in the Evolving Biopharma Landscape
2
Clearing Hurdles in Sustainability, AI, and CDMO Partnerships
3
Excipient Innovation and the Regulatory Tug-of-War: Navigating Threats to Availability and Safety
4
Standardizing Operations to Meet Global Sustainability and Resilience Goals
5
